Myocardial deformation links combined liraglutide-empagliflozin therapy with improved cardiovascular and economic outcomes in type 2 diabetes: a 6-year study - PubMed
5 hours ago
- #cardiovascular outcomes
- #combined therapy
- #type 2 diabetes
- Combined liraglutide-empagliflozin therapy in type 2 diabetes showed the greatest improvement in left ventricular global longitudinal strain (LVGLS) at 6 months compared to insulin, GLP-1RA, or SGLT2i alone.
- Over a 6-year follow-up, the combination therapy group had the lowest risk of non-fatal cardiovascular events, with hazard ratios significantly favoring it over insulin, GLP-1RA, and SGLT2i monotherapies.
- Improvement in LVGLS within the combination group independently predicted reduced cardiovascular risk, highlighting myocardial deformation as a key mediator.
- Cost analysis revealed the combination therapy resulted in the lowest mean healthcare cost per patient per month, demonstrating economic benefits alongside clinical outcomes.
- The study concludes that early myocardial deformation improvements from combined GLP-1RA and SGLT2i therapy translate into long-term cardiovascular risk reduction and favorable economic outcomes in type 2 diabetes.